IRYCIS
Biomarkers to identify IFN-BETA drug responders in patients with multiple sclerosis
Biomarkers / Diagnostic
Autoimmune & Inflammation
Central Nervous System
New patented method to identify good responders to Interferon beta (INF-beta) therapy in multiple sclerosis before treatment initiation
5Ready to Market,
4Register,
3Clinical validation,
2Preclinical Validation,
1R+D
Spain